UCLPartners Proactive Care Framework:

Atrial Fibrillation – Stroke Prevention and Managing Cardiovascular Risk

Version 7



The Proactive Care Frameworks can be used independently. To request the search tools please visit: <u>UCLPartners Proactive Care Frameworks -</u> <u>UCLPartners</u>

They can also be used in conjunction with **<u>CVDACTION</u>**



Background to the Frameworks



The Challenge of Long-Term Condition Management in Primary Care



Historical challenge in long term condition care:

- Late diagnosis, suboptimal treatment, unwarranted variation
- Lack of self-management support
- Holistic care not always provided



Real world primary care:

- Complexity, multimorbidity and time pressures
- Soaring demand and shifting priorities
- Winter pressures

Pandemic impact:

- Disruption of routine care in long term conditions
- Risk of poorer outcomes for patients and health inequalities

UCLPartners Health Innovation

• An increase in health care demand

UCLPartners Proactive Care Frameworks Address Core Challenges in Primary Care

Aim

Help people with long term conditions to stay well longer

Objectives

- Mobilise data Identify patients whose care needs optimising and prioritise those at highest risk
- 2. Harness wider workforce standardise delivery of holistic proactive care by wider primary care team
- 3. Support GPs to safely manage workflow, improve care and outcomes by releasing capacity

Framework components

- ✓ Risk stratification & prioritisation tools
- Locally adaptable resources to support real world management
- Systematic use of wider primary care team (eg ARRS* roles) to deliver structured support for education, self-management and behaviour change

Framework Development

- Led by primary care clinicians
- Based on NICE guidelines and clinical consensus
- Patient and public support




Cardiovascular Disease (CVD) Conditions – Stratification and Management

ARRS ^{\$} roles/ other appropriately trained staff	 Gather information e.g. Up to date bloods, BP, weight, smoking status, run risk scores: QRISK*, CHA₂DS₂VASc, HASBLED. Self management e.g. Education (condition specific, CVD risk reduction), self care (eg red flags, BP measurement, foot checks), signpost shared decision making. Behaviour change e.g. Brief interventions and signposting e.g. smoking, weight, diet, exercise, alcohol. 					
Risk Stratification & Prioritisation	Atrial Fibrillation	Blood Pressure	Cholesterol	Diabetes		
Optimise therapy and mitigate risk Review blood results, risk scores & symptoms. Initiate or optimise therapy. Check adherence and adverse effects. Review complications and co-morbidities. CVD risk – BP, cholesterol, pre-diabetes, smoking, obesity.						



*QRISK 3 score is recommended to assess CV risk for patients with Severe Mental Illness, Rheumatoid Arthritis, Systemic Lupus Erythematosus, those taking antipsychotics or oral steroids

^{\$}Additional Roles Reimbursement Scheme



Why Atrial Fibrillation? -The Case for Change



Why the Focus on Atrial Fibrillation and Cardiovascular Risk?



Atrial fibrillation (AF) leads to a 5-fold increased risk in stroke and is responsible for 20% of all strokes. Anticoagulation reduces the risk of stroke by up to two thirds¹.



If not anticoagulated, 25% of people who experience an AF-related stroke will die and over 50% of people will be left with moderate to severe disability². Each stroke costs the NHS and social care over £45k over 5 years³.



For most people, the benefits of anticoagulation significantly outweigh the risks.




People with AF are more likely to also have high blood pressure, high cholesterol, obesity or smoke. These factors should be addressed routinely to reduce the risk of heart attack, peripheral arterial disease, and dementia.





References: 1. Hart et al, 2007; 2. Stroke Association, 2018; 3. Xu et al, 2017;

Stratification and Management of Atrial Fibrillation (AF)



Atrial Fibrillation: Stratification and Management of Stroke Risk





^{\$}Additional Roles Reimbursement Scheme

Health Innovation

Pathways and Resources



Pathways and Resources

- 1. Initiating Direct Oral Anticoagulants (DOACs)
- 2. Assessing stroke and bleeding risk
- 3. DOACs: Calculating creatinine clearance
- 4. DOACs: Dosing in non-valvular atrial fibrillation
- 5. DOACs: Reviewing condition management
- 6. DOACs: Considerations
- 7. Anticoagulation in people taking antiplatelet therapy
- 8. <u>Warfarin: Time in therapeutic range (TTR) monitoring</u>
- 9. Warfarin to DOAC switching
- 10. DOAC to DOAC switching



Initiating Direct Oral Anticoagulants (DOACs)*

Action	Resource
1 Check the patient has Non-Valvular AF (NVAF) and has no other contraindications to therapy	DOAC contraindicated if mechanical prosthetic valve or known moderate to severe mitral stenosis DOAC contraindicated if pre-existing clotting disorder, such antiphospholipid syndrome (APS) pregnant, breastfeeding or planning pregnancy, mechanical heart valves – seek specialist advice. For full list of contraindications see SmPCs at www.medicines.org.uk
2 Check CHA ₂ DS ₂ VASc	Offer anticoagulation if $\underline{CHA_2DS_2VASc} \ge 2$ (consider if = 1 in men)
 Check: Bloods for renal function, LFTs, clotting and FBC Bodyweight Creatinine Clearance (CrCl) 	<u>Creatinine clearance calculation</u> Dabigatran contraindicated if CrCl < 30ml/min Apixaban, Edoxaban, Rivaroxaban, are not recommended if CrCl < 15ml/min
4 Check bleeding risk with HASBLED score or ORBIT score, in line with local guidance	Address modifiable risks identified by <u>HASBLED or ORBIT score</u> to reduce bleeding risk. Review other medication – <u>including antiplatelets</u> and NSAIDs; consider PPIs
5 Shared Decision Making (SDM) - agree which DOAC to initiate. Correct choice of dose	DOAC dosing
6 Counsel patient and agree a plan for follow up including monitoring blood tests	DOAC monitoring Provide written information, an anticoagulant alert card and point of contact should issues arise
*NICE guidance 2021 recommends D	OACs first line If DOAC is unsuitable consider warfarin following

local pathways for initiation & monitoring



Stroke Risk Assessment

Stroke Risk						
CHA ₂ DS ₂ VASc		CHA ₂ DS ₂ VASc Score	Number of AF-related strokes avoided per 1,000 AF patients			
Congestive Heart failure	1		treated with anticoagulant			
Hypertension	1		therapy per year*			
Age >75 years	2					
Diabetes	1	1	4			
Prior stroke/TIA	2	2	17			
Vascular disease	1	3	25			
Age 65-74 years	1	4	38			
Female	1	5	57			

Interpretation

- 1. Offer anticoagulation to all patients (male or female) with $CHA_2DS_2VASc \ge 2$
- 2. Consider anticoagulation in all men with $CHA_2DS_2VASc = 1$
- 3. Antiplatelet monotherapy (Aspirin/Clopidogrel) is not recommended for stroke prevention in AF



*Tables adapted from Y Javaid

Bleeding Risk Assessment

Bleeding Risk (HASBLED)				Bleed	ing R	isk - Ol	RBIT		
HASBLED Score		Throbeed Trainber of		ORBIT Score**		ORBIT Score	Risk level	Number of major bleeds	
Uncontrolled hypertension (systolic >160mmHg)	1	Score	major bleeds caused per	Haemoglobin <13 mg/dL for males and <12 mg/dL for	2	Score		caused per 1,000 AF	
Abnormal liver function (Bili >2x ULN or AST/ALT/ALP >3x ULN	1		1,000 AF patients	females, or haematocrit <40% for males and <36% for				patients treated with anticoagulant	
Abnormal renal function (Creat>200µmol/L, dialysis, transplant)	1		treated with anticoagula nt therapy	females Age >74 years	1			therapy per year	
Prior stroke/TIA	1		per year*						
History of major bleed or predisposition (anaemia)	1	1	4	Bleeding history - Any history of GI bleeding, intracranial bleeding, or haemorrhagic	2	0-2	Low	24	
Labile INR (on warfarin (TTR<60%)	1	2	12	stroke		2	Madiuma	47	
Age >65 years	1	2	12	GFR <60 mL/min/1.73 m2		3	Medium	47	
Medication usage predisposing to bleeding (Antiplatelets/ NSAIDS)	1	3	15	Treatment with antiplatelet agents	1	4-7	High	81	
Alcohol (>8units/week)	1	4	21	**NICE 2021 indicated that ORBIT is the best tool for bleeding risk assessment, oth					

Interpretation

- 1. HASBLED \geq 3 indicates a higher bleeding risk
- 2. Address modifiable bleeding risk factors to reduce HASBLED score e.g. lower BP, review concomitant drug therapy, reduce alcohol intake
- 3. Consider a proton pump inhibitor to reduce upper GI bleeding <u>https://www.mdcalc.com/has-bled-score-major-bleeding-risk</u>

may need to be used until it is embedded in clinical pathways and electronic systems

Interpretation

- 1. Address modifiable bleeding risk factors to reduce bleeding risk e.g. lower BP, review concomitant drug therapy, reduce alcohol intake
- 2. Consider a proton pump inhibitor to reduce upper GI bleeding

https://www.mdcalc.com/orbit-bleeding-risk-score-atrial-fibrillation

Health Innovation

*Tables adapted from Y Javaid

Ref: European Heart Journal, Volume 36, Issue 46, 7 December 2015, Pages 3258–3264, https://doi.org/10.1093/eurheartj/ehv476

DOACs: Calculating Creatinine Clearance

eGFR should not be used to guide dosing decisions for DOACs¹

Use actual bodyweight (within 1 year) to calculate Creatinine Clearance (CrCl)

• If weight < 50kg or > 120kg or if BMI >40 : seek specialist advice

Use renal function checked within last 3 months

Calculate CrCl using Cockcroft Gault equation	CrCl	Monitoring interval
 Be cautious with calculators integrated into GP IT systems as they may default to ideal bodyweight resulting in underdosing of DOAC Use MDCalc 	>60ml/min	Annually
	30- 60ml/min	6-monthly
	<30ml/min	3-monthly

Adjust DOAC dose if necessary See slide on DOAC dosing in NVAF



DOACs: Dosing in Non-Valvular Atrial Fibrillation

	Apixaban*	Dabigatran	*	Edoxaban*	Rivaroxaban*
Standard dose	5mg BD	150mg BD		60mg OD	20mg OD
Reduced dose	2.5mg BD	110mg BD		30mg OD	15mg OD
Criteria for dose reduction	2 or more of: • <u>Age</u> ≥80 • <u>B</u> ody weight ≤60kg • <u>C</u> r ≥133µmol/L Or CrCl 15-29ml/min	 Age≥80 On verapar Consider ↓c Reflux/gas Age75-80 CrCl 30-50 "Bleed risk 	lose: tritis ml/min	 1 or more of: CrCl 15-50ml/min Body weight ≤60kg On ciclosporin, dronedarone, erythromycin, ketoconazole 	CrCl 15-49ml/min
Contraindicated / Not recommended	CrCl <15ml/min	CrCl <30ml/min		CrCl <15ml/min	CrCl <15ml/min
	ck for common drug inte sible contraindications	eractions &	Bleeding r	isk increased by	
Antifu	ungal agents		NSAIDs		
Rifampicin Phenytoin and anti-epileptics			Antiplatelets		
		Long term oral steroid use			
Antir	Antiretrovirals		Antidepressants: SSRIs/SNRIs		
Chemotherapy					UCLPartners Health Innovation

DOACs: Reviewing Management

This review template is designed for review 1 month after initiation and according to the monitoring interval

Eligibility	Monitoring interval	Parameter	Annual clinical review* to include:
All patients on DOAC	Annually	FBC, Renal & Liver function (calculate CrCl, weight)	Stroke risk assessment usi
• CrCl 30–60 mL/min	6 monthly	Renal function	 CHA₂DS₂VASc Review of QRISK and mana
 Patients over 75 years and / or frail 	6 monthly	FBC, Renal & Liver function, weight	CVD risk factors including and lipids
• CrCl 15–30 mL/ml	3 monthly	Renal function	 Address bleeding risk
• Other e.g. intercurrent illness that may impact on renal or hepatic function	Individually agreed	Renal & Liver function +/- FBC	 Check adherence Medicines review and check

Alternatively, NICE CKS recommends that where CrCl < 60ml/min, monitoring frequency should be guided by the CrCl divided by 10. For example, every 3 months if CrCl is 30 mL/minute. https://cks.nice.org.uk/topics/anticoagulation-oral/management/edoxaban/

- sing
- nage BP
- eck appropriate dosing
- Missed/delayed dose advice ٠
- Alert card check ٠



* Follow local DOAC clinical review protocols where available

DOACs: Considerations

Consideration	Option	Most suitable DOAC
Frequency of tablets/capsules	One tablet once a day	Edoxaban/rivaroxaban
Frequency of tablets/capsules	One tablet or capsule twice a day	Apixaban/dabigatran
With or without food	Take with or without food	Apixaban/dabigatran/edoxaban
	Take with food	Rivaroxaban
	Suitable to go in compliance aid	Apixaban/edoxaban/rivaroxaban
Use of a compliance aid (dosette box)	(Cannot use dabigatran in dosette box)	
	CAN be crushed	Apixaban/edoxaban/rivaroxaban
Swallowing difficulties or feeding tube	Capsules CANNOT be opened	Dabigatran
Lactose intolerant patient		Dabigatran/edoxaban



Anticoagulation in People Taking Antiplatelet Therapy

- Antiplatelet therapy is not recommended for stroke prevention in AF; oral anticoagulants should be used.
- Some patients with AF are on antiplatelet therapy as treatment for vascular disease. See guidance below

Indication for antiplatelets	Antiplatelet	Action when initiating anticoagulation for AF
Primary prevention of CVD	Antiplatelet monotherapy	Stop antiplatelet therapy (antiplatelet therapy not recommended for primary prevention of CVD)
 Secondary prevention of CVD Stroke / Transient Ischaemic Attack (TIA) Stable coronary heart disease (CHD) Peripheral arterial disease (PAD) 	Antiplatelet monotherapy or Low dose rivaroxaban with aspirin	Stop antiplatelet therapy Increase DOAC dose (to AF stroke prevention dose) and stop aspirin
Patients within 12 months of an ACS or stent placement (cardiac or vascular)	Aspirin plus clopidogrel, ticagrelor or prasugrel	Seek specialist advice to agree the preferred drug regimen. Triple therapy (dual antiplatelet plus anticoagulant) duration must be clearly defined.
Patients more than 12 months after an ACS or stent placement (cardiac or other vascular)	Antiplatelet monotherapy / dual antiplatelet therapy	Stop antiplatelet therapy, unless otherwise advised by specialist (check discharge summary)
	If discharge summary indicates dual antiplatelet required long-term	Seek specialist advice – do not initiate triple therapy without advice

When using an anticoagulant plus an antiplatelet – add a proton pump inhibitor (PPI)

Adapted from: <u>https://b-s-h.org.uk/guidelines/guidelines/oral-anticoagulation-with-warfarin-4th-edition/</u> Page 318-319 and <u>https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Atrial-Fibrillation-Management</u> Page 61



Warfarin: Time in Therapeutic Range (TTR) monitoring

- For effective stroke prevention with warfarin, time in the rapeutic range (TTR) should be maintained \geq 65%
- INR should be checked at least 12 weekly in patients with stable INR target INR in AF is 2.5 (range 2-3)
- All patients should have TTR calculated at each INR visit
- Reassess anticoagulation if poor control as shown by:
 - 2 INR values > 5 or 1 INR value > 8 within the past 6 months
 - 2 INR values < 1.5 within the past 6 months
 - o TTR less than 65%
- If possible, address modifiable factors that may contribute to poor control:
 - o Adherence, illness, interacting drugs, diet and alcohol consumption

NICE guidance recommends that patients prescribed warfarin for stroke prevention in AF should be considered for a swich to DOAC. Switching to a DOAC should be discussed with patients who are stable on warfarin at their next routine review, taking into account their time in therapeutic range.



Warfarin to DOAC Switching

- Confirm the indication for warfarin is stroke prevention in AF
- Exclude patients with contraindications to DOACs
- Involve the patient in a <u>shared decision</u> to switch from warfarin to a DOAC 3
- Check bodyweight and bloods for INR, renal function, LFTs, and FBC
- Calculate CrCl using Cockcroft Gault equation 5
- Decide which <u>DOAC to use</u> and what <u>dose</u> 6
 - Advise patient when to stop the warfarin and start the DOAC:
 - INR should be <2.5 before initiating DOAC
 - DOAC may need to be withheld or 24-48 hours after stopping warfarin ٠ depending on the measured INR
- 8

Provide written information, an anticoagulant alert card and ensure they have a point of contact should issues arise

КСРА Primary Care Cardiovescular Society \mathbf{a} PCPA Anticoagulation for non-valvular atrial fibrillation (NVAF) following NHSE DOAC commissioning recommendations Published July 2022 Additional information on switching from warfarin to a DOAC Suggested presents for sole numbering from workering to a EOMC: 5. Cleack record UBAs, Driv and PRC (cleakly worker the last of number) and uncoder-It is for the prescribing clinician to determine which DOAO(s) are dinically appropriate for an individual patient based upon the relevant constitutes the same Kirth Street News, which for shared as to choose NICE technology approint guidance. s/asimiliuse adjusted bedownight if parlents = 120kg / 8Mils Alb When awitching to a DOAC, care should be taken to follow the recommendations : Cherry 845 Discuss options with your patient and/or carers (incleptoproted and, with cares resulting OOAC at advancements cause - educate a protor red first-time use over the Ediptics [Podes/Hips//www.endetes.org.at/end/and/ATRI/arg Remover warfarie fram the repeat prescription after reliating DCML Could's the industrial of COMP a supersymptotic difference and the description for starting COMP. opping worksite. The CHRA should be < 2.5 where the DOAL is starte A savite is its an available to a DIGAC should not be considered for writer · I PRICE Companyon DOM: TON A I PR batwoon 2 and 2.5 Commence DCMC the next day ideally for With mode up to revenue to 2 of day part same day! With antighospholipid antibody systrome (Rull) (social where advand by a # Bill between 2.5 and 3 in East DOAC fent mi unt spieche feb When are represent beyond distributive to existence a representation Requiring a higher that this the standard this range of 20 - 3.0 MINISTERATION AND ADDRESS With severa canal impairment - Chestinane Clearance (C)(C) < C)(C)// in resident weithing instituted on a land investor from With enious thrombons at analysis sites (e.g. ports ven thrombons) existing the tripling patients, taking both works to used the care incuto be taken where cellents are using medication compliance add to remain the lisk of incontect doxing

devices and an entry of the second states mbed enteractions drugs - check SniPCs for full least Some is 9 onther rowings and head the anti-from - check with NW desc interactions weather or international discharge and ionthickness or affectively an er unitydeptics pheryicis, and encarying al-Melpin review DOM overs as deniable descent which as a dimersionly being On price therapy ideal antibiotelet therapy plus working



earterie-



Provide an up-to-date Articology and Mert and DOWC counselling t Mitseen the special loss (2000) is understation and take the GP at

function a hospitate you'l depend to a real function, age and hally

single symptotic to safely taken over more distort times will dill a more community surging tasks if they have been monitoric

Presare a going to let us going normalizing is in plan

information reliably to reflection, baseling incides and manifesting requirements in all

DOAC to DOAC Switching

Confirm the indication for DOAC is stroke prevention in AF

- Identify any reasons why a switch to an alternate DOAC may not be suitable e.g, specific contraindications or cautions etc
- 3

8

- Involve the patient in a <u>shared decision</u> to switch to an alternative DOAC
- Check bodyweight and bloods for INR, renal function, LFTs, and FBC
- 5 Calculate CrCl using <u>Cockcroft Gault equation</u>
- Decide which <u>DOAC to use</u> and what <u>dose</u>
- Advise patient when to stop the existing DOAC and to start the alternative DOAC:
 - Continue existing DOAC as normal on day before the switch
 - Initiate alternative DOAC when next dose is due on day of switch.
 - Ensure patient understands if dosing is once or twice daily, depending on DOAC
- Provide written information, an anticoagulant alert card and ensure they have a point of contact should issues arise


Cardiovascular Sacley





Anticoagulation for non-valvular atrial fibrillation (NVAF) following NHSE DOAC commissioning recommendations

Published July 2022



https://pccsuk.org/2020/en/page/resources-page



Hypertension in Patients with Atrial Fibrillation




Detection and Management of Hypertension in Patients with Atrial Fibrillation


- Blood pressure should be checked in patients with AF to identify undiagnosed hypertension. If hypertension is suspected due to a high BP reading, the diagnosis should be confirmed using ABPM or home BP checks over 7 days.
- Checking BP in patients with established hypertension:
 - Patients **with** AF:
 - Submit 2 BP readings each morning and evening over 4 days. Calculate the average systolic and diastolic values.
- Please refer to UCLP hypertension pathway for detailed guidance: <u>CVD resources UCLPartners</u>



Home Blood Pressure Monitoring Pathway




NICE Hypertension Treatment Pathway (NG136)



Offer lifestyle advice and continue to offer it periodically	Monitoring treatmentUse clinic BP to monitor treatmentMeasure standing and sitting BP in people with:• Type 2 diabetes or• Symptoms of postural hypotension or• Aged 80 and overAdvice people who want to self monitor to use HBPM. Provide training and adviceConsider AMPM or HBPM, in addition to clinic BP, for people with white-coat effect or masked hypertensionBP targets Reduce and maintain BP to the following targets:Age <80 years: • Clinic BP <140/90 mmHg
	Use clinical judgement
ay adapt	ed from NICE Guidelines (NG136) Visual Summary
/www.ni	ice.org.uk/guidance/ng136/resources/visual-summary-pdf-68999195

https://www.nice.org.uk/guidance/ng136/resources/visual-summary-pdf-6899919517 Abbreviations: ACEi: ACE inhibitor, ARB: Angiotensin II Receptor Blocker, CCB: Calcium Channel Blocker, ABPM: Ambulatory Blood Pressure Monitoring, HBPM: Home Blood Pressure Monitoring





Management of Broader Cardiovascular Risk in AF: Cholesterol



Managing High Cholesterol and Cardiovascular Risk in People with Atrial Fibrillation

The following slides will help clinicians manage the broader cardiovascular risk in people with atrial fibrillation:

- Pre-existing cardiovascular disease
 - o Optimise lifestyle
 - o Use of high intensity statins at maximal appropriate dose


No pre-existing cardiovascular disease

- Optimise lifestyle and lipid lowering therapy as primary prevention in people with:
 - QRisk >10% in ten years
 - CKD 3-5
 - Type 1 Diabetes for >10 years or over age 40
- All patients:
 - Responding to possible statin intolerance
 - Managing muscle symptoms and abnormal LFTs in people taking statins
- Please refer to UCLP lipid pathway for detailed guidance:


https://uclpartners.com/our-priorities/cardiovascular/proactive-care/cvd-resources/



Lipid Optimisation Pathway for Secondary Prevention¹



Optimisation Pathway for Patients with High Cardiovascular Risk – Primary Prevention^{1,2}



Statin Intolerance Pathway

Important considerations


- Most adverse events attributed to statins are no more common than placebo¹
- Consider food and drug interactions which may be contributing to adverse effects – see Summary of Product Characteristics (SmPC)^{2,3}
- Stopping statin therapy is associated with an increased risk of major CV events. It is important not to label patients as 'statin intolerant' without structured assessment
- If a person is not able to tolerate a high-intensity statin, aim to treat with the maximum tolerated dose
- A statin at any dose reduces CVD risk consider annual review for patients not taking statins to review cardiovascular risk and interventions

A structured approach to reported adverse effects of statins

- Stop for 4-6 weeks.
- If symptoms persist, they are unlikely to be due to statin
- Restart and consider lower initial dose
- If symptoms recur, consider trial with alternative statin
- If symptoms persist, consider <u>ezetimibe</u> +/- <u>bempedoic acid</u>
- 1. (Collins et al systematic review, Lancet 2016)
- 2. SmPC: Atorvastatin
 - https://www.medicines.org.uk/emc/product/5274/ smpc#gref
- 3. SmPC: Rosuvastatin <u>https://www.medicines.org.uk/emc/product/4366/</u> <u>smpc#gref</u>



Digital Resources



Digital Resources to Support Self-Management: Atrial Fibrillation

Living with Atrial Fibrillation

British Heart Foundation <u>Living with Atrial Fibrillation</u>; <u>AF causes, symptoms and treatments</u> The AF Association <u>Patient resources</u> NHS website – <u>Anticoagulant medicines</u> Stroke Association – Blood thinning medication and stroke, AF symptoms, diagnosis and treatment, AF and stroke

Blood Pressure British Heart Foundation Managing blood pressure at home

Starting anticoagulation Starting anticoagulation with Jack - <u>https://vimeo.com/206257430</u>

Educational video resources for patients created by UCLPartners - https://uclpartners.com/work/anti-coagulation-videos/

Diet

Providing information and recipes for easy ways to eat better from the <u>'Better Health'</u> website <u>NHS advice on lowering cholesterol levels & what is cholesterol and how do I lower it?</u>

Smoking cessation <u>NHS support</u>, stop smoking aids, tools and practical tips Alcohol Heart UK alcohol guidance & NHS Drink Less guidance

Exercise

NHS <u>'Better Health'</u> Tips, advice and guidance on how to keep or get active in and around the home: <u>Getting active around the home</u> Dance to health: <u>Online dance programme</u> especially tailored to people over 55 years old The Richmond Group of Charities: <u>Physical activity videos and information</u>



Digital Resources to Support Clinical Management: Atrial Fibrillation

Video resources (What is anticoagulation; I am on a DOAC; Starting a DOAC; Anticoagulation in VT; Anticoagulation in atrial fibrillation; Switching from warfarin to a DOAC) created by UCLPartners https://uclpartners.com/work/anti-coagulation in atrial

Cockcroft-Gault Equation <u>https://www.mdcalc.com/creatinine-clearance-cockcroft-gault-equation</u>

RCGP Module

The Royal College of General Practitioners e-module on Atrial Fibrillation: diagnosis and management. Access <u>here</u> (log in details required)

Locally commissioned digital tools:

AF Toolkit – <u>www.aftoolkit.co.uk</u>

UCLP Proactive Care resources to address additional CVD and respiratory conditions can be accessed here





Implementation Support



Proactive Care Frameworks: Implementation & Support Package

Implementation Support is critical to enable sustainable and consistent spread. UCLPartners has developed a support package for the Integrated Care Systems within our geography covering the following components. The resources below can be accessed via the UCLP website: **Proactive care frameworks – UCLPartners**.

UCLPartners is one of 15 <u>Health Innovation Networks (HINs</u>) across England and all 15 have a priority around CVD. Please reach out to your local HIN to understand what support they might be able to provide. Please note each varies in its approach and offer.

Search and stratify	 Comprehensive search tools for EMIS and SystmOne to stratify patients Pre-recorded webinar as to how to use the searches. Online FAQs to troubleshoot challenges with delivery of the search tools.
Workforce training and support	 Training tailored to each staff grouping (e.g. some ARRS* roles) and level of experience Delivery: Scripts provided as well as training on how to use these underpinned with motivational interviewing/ health coaching training to enable adult-to-adult conversations. Practical support: Recommended training e.g. correct inhaler technique; correct BP technique, Very Brief Advice for smoking cessation, physical activity etc. Digital implementation support: how to get patients set up with appropriate digital. Education sessions on conditions. Communities of Practice.
Digital support tools	Digital resources to support remote management and self-management in each condition. Implementation toolkits available where required, e.g. MyCOPD. Support available from UCLP's commercial and innovation team for implementation.



Thank you

Sign up to our monthly newsletter to receive the latest news, opportunities and events from UCLPartners



UCLPartners.com/newsletter

For any enquiries, please contact us via email:

primarycare@uclpartners.com



- www.uclpartners.com
- <u>@uclpartners</u>
- in linkedin/company/uclpartners
 - <u>comms@uclpartners.com</u>



Version tracker

Version	Edition	Changes Made	Date amended	Review due
2	2.0	 Incorporated hypertension and cholesterol management content for patients with multi- morbidity 		
2	2.1	Amended version control table to include dates and removed date from first slide	June 2021	December 2021
3	3.0	 Removed slide on resources for remote diagnostics and monitoring Amended information on cholesterol management Removed statistics on statins and statin intensity table Added ORBIT bleeding risk tool Added option of bempedoic acid 	August 2021	February 2022
4	4.0	 Updated warfarin to DOAC slide Updated DOAC to DOAC slide Updated cholesterol pathways Updated resource slides 	October 2022	October 2023
5	5.0	 Introduction slides updated HCA roles amended to ARRS roles Lipid pathway treatment targets updated to align with NICE and AAC guidance 	December 2022	December 2023
5	5.1	 Updated cholesterol pathway slides Amended introduction slides 	September 2023	September 2024
6	6.0	 Cholesterol pathways updated Implementation slide updated 	January 2024	January 2025
6	6.1	New UCLP template	April 2024	January 2025
7	7	Lipid Optimisation pathway for secondary prevention updated.	June 2024	January 2025